BridgeBio have substantially improved its development of an new therapy for cardiac amyloidosis, employing the investigational drug. Initial trial data suggests potential benefits for patients suffering from the severe https://attrcm562087.wizzardsblog.com/42043317/bridgebio-progresses-attr-cm-management-with-the-therapy